Related Experiment Video
Updated: Jun 12, 2025
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
Christopher S Hackett1,2,3, Daniel Hirschhorn2,3, Meixian S Tang2,3
1Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Abstract:
Despite therapeutic efficacy observed with immune checkpoint blockade in advanced melanoma, many tumors do not respond to treatment, representing a need for new therapies. Here, we have generated chimeric antigen receptor (CAR) T cells targeting TYRP1, a melanoma differentiation antigen expressed on the surface of melanomas, including rare acral and uveal melanomas. TYRP1-targeted CAR T cells demonstrate antigen-specific activation and cytotoxic activity in vitro and in vivo against human melanomas independent of the MHC alleles and expression. In addition, the toxicity to pigmented normal tissues observed with T lymphocytes expressing TYRP1-targeted TCRs was not observed with TYRP1-targeted CAR T cells. Anti-TYRP1 CAR T cells provide a novel means to target advanced melanomas, serving as a platform for the development of similar novel therapeutic agents and as a tool to interrogate the immunobiology of melanomas.
Insights
New chimeric antigen receptor (CAR) T-cells targeting TYRP1 show promise for treating advanced melanoma. These TYRP1-CAR T-cells are effective against various melanomas without harming normal tissues.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Advanced melanoma remains challenging, with many patients unresponsive to current immune checkpoint blockade therapies.
- There is a critical need for novel therapeutic strategies to improve treatment outcomes for melanoma patients.
Purpose of the Study:
- To develop and evaluate chimeric antigen receptor (CAR) T-cells targeting Tyrosinase-Related Protein 1 (TYRP1) for advanced melanoma treatment.
- To assess the efficacy and safety of TYRP1-targeted CAR T-cells in preclinical models.
Main Methods:
- Generation of CAR T-cells engineered to target TYRP1, a melanoma-associated antigen.
- In vitro and in vivo testing of TYRP1-CAR T-cell activity against human melanoma xenografts.
- Evaluation of CAR T-cell specificity, cytotoxic function, and potential toxicity to normal tissues.
Main Results:
- TYRP1-targeted CAR T-cells exhibited antigen-specific activation and potent cytotoxic activity against human melanomas in vitro and in vivo.
- Therapeutic efficacy was observed independently of MHC allele expression.
- Unlike TCR-based approaches, TYRP1-CAR T-cells did not cause toxicity in normal pigmented tissues.
Conclusions:
- TYRP1-CAR T-cells represent a promising novel therapeutic approach for targeting advanced melanomas, including rare subtypes.
- This platform offers potential for developing new melanoma therapies and serves as a tool for immunobiology research.
